NCT03799172

Echinocandins Versus Azoles for Candidemia Treatment

Echinocandins Versus Azoles as First-line Therapy for the Treatment of Candidemia in Intensive Care Units

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 79 (actual)
• Sponsor: Hospices Civils de Lyon · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

Candidemia is the most frequent invasive fungal disease in intensive care units (ICUs). It remains a major health concern, considering its attributable mortality up to 40% in critically ill patients. Successful clinical outcome requires early diagnosis and effective antifungal therapy. Guidelines for the treatment of candidemia were published by the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). According to these guidelines, echinocandins are the preferred first-line therapy for candidemia in critically ill patients. Considering the bibliography supporting this statement, the place of triazoles still needs to be defined in candidemia therapeutic arsenal. In this context, we are setting up a retrospective cohort study using Hospital database to compare the efficacy of echinocandins and azoles for the treatment of candidemia in intensive care units.

Conditions

• Candidemia

Interventions

Type	Name	Description
DRUG	Echinocandin treatment	Patients received echinocandins as a first-line therapy after candidemia diagnosis according to the standard of care
DRUG	Triazole treatment	Patients received triazoles as a first-line therapy after candidemia diagnosis according to the standard of care. Candidemia was defined as at least one blood culture positive for Candida.

Timeline

• Start date: 2018-11-01
• Primary completion: 2019-02-01
• Completion: 2019-09-01
• First posted: 2019-01-10
• Last updated: 2020-03-04

Locations

1 site across 1 country: France